Increasing antibiotic resistance urgently requires novel therapeutic options to combat bacterial infections. The anti-virulence therapy selectively intervening with pathogenicity without affecting bacterial viability is such a strategy to overcome resistance. We consider the virulence regulator PqsR as an attractive target in the human pathogen Pseudomonas aeruginosa, and recently discovered the first PqsR antagonists, which, however, suffered from poor aqueous solubility. In this work, the antagonists were structurally modified to become more soluble, and their structureactivity as well as structure-property relationships were studied. A novel promising compound with improved solubility and enhanced anti-virulence activity was discovered (IC 50 : 3.8 µM, pyocyanin). Our findings emphasize the crucial role of substituents at the 3-position and the carbonyl group at the 4-position for ligandreceptor interactions, and illuminate the way for further optimization of PqsR antagonists as anti-virulence agents.
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Introduction
The opportunistic human pathogen Pseudomonas aeruginosa is one of the most common causes of nosocomial infections and a major problem in cystic fibrosis (CF) patients leading to inflammation, chronic persistent lung infections and high mortality [1, 2] . Like many other pathogenic bacteria, P. aeruginosa expresses a battery of tissue-damaging virulence factors to facilitate infection via a cell density dependent cell-to-cell communication system known as quorum sensing [3] by secreting and sensing of signal molecules termed autoinducers (AIs). P. aeruginosa utilizes a unique species-specific pqs QS system [4] , which is composed of two AIs, PQS (Pseudomonas Quinolone Signal, Chart 1) and HHQ (2-heptyl-4-hydroxyquinoline), as well as PqsR which functions as a receptor and a virulence regulator [5, 6] . The pqs QS system regulates expression of multiple virulence genes, such as phzA1-G1, which are involved in the biosynthesis of pyocyanin, hcnAB, responsible for the production of hydrogen cyanide, and lasB, which encodes elastase B [5, 7] . Besides, PqsR drives the biosynthesis of its AI HHQ through activation of the pqs operon pqsABCD. HHQ is further converted to the more potent PQS by PqsH [8, 9, 10] . Thus, a positive autoinducing loop is triggered via stimulation of PqsR by PQS and HHQ [11] .
The anti-virulence therapy using QS inhibitors (QSIs) selectively intervening with pathogenicity, e.g. by repressing the production of virulence factors, without impairing bacterial viability is discussed as an alternative approach to conventional anti-bacterial therapy. It is supposed that in anti-virulence therapy the selection pressure is reduced. This treatment option is therefore regarded as a promising strategy to overcome the rising and challenging resistance problem [12, 13, 14] .
The critical virulence regulator PqsR has attracted rising attention by researchers as a favorable target for QSIs [15, 16] . Based on the scaffold of the natural agonist HHQ,
we recently developed the first PqsR antagonists. The compounds showed IC 50 values in the low nanomolar range (Chart 1) and reduced the production of the virulence factor pyocyanin in P. aeruginosa [17] . However, a major drawback of these compounds is their poor aqueous solubility (<5 µM in 2% DMSO). This physicochemical property is essential for a compound to be considered as a drug candidate since a good solubility is important for pharmacokinetic properties [18] .
Insufficient solubility is often the cause for failures in drug development [19] . Aiming at the improvement of the aqueous solubility we herein describe structure modifications of our PqsR antagonists and their impact on the biological properties of the new compounds, and discuss the obtained structure-activity (SAR) as well as structure-property relationships (SPR).
Results and discussion

Design
First, we suspected that the intermolecular stacking [20] or H-bond between the NH group at 1-position and the carbonyl group at 4-position may contribute to the poor solubility. Thus, a methyl group was introduced to block such interactions (compound class 1, Chart 2). Second, to increase the hydrophilicity, polar or ionisable groups were introduced into the molecule: oxygen was inserted into the alkyl side chain (compound class 2); the 3-position was substituted with e.g. amide, amino, carboxylic or hydroxamic acid groups (compound class 3); the benzene moiety substituted with electron withdrawing groups was replaced by pyridine (compound class 4). The structure modifications were performed based on antagonist 2 due to the good synthetic accessibility of the nitro compounds. with lithium aluminium hydride gave the hydroxymethyl compound 15 (Scheme 2).
Biological and physicochemical properties
The PqsR-mediated transcriptional effect of the compounds was evaluated as previously described in a β-galactosidase reporter gene assay in E. coli containing the plasmid pEAL08-2. The latter encodes PqsR which is under control of the tac promoter and the β-galactosidase reporter gene lacZ controlled by the pqsA promoter.
The solubility was initially determined based on observation of the solution clarity [17] . The eight best compounds were chosen for determination of PqsR antagonistic properties and calculation of logP values. Their aqueous solubility was determined using a standard HPLC protocol [21] .
Compound class 1.
The O-methylation of HHQ decreased the solubility of the molecule and led to neither agonistic nor antagonistic activity (3, Table 1 ), suggesting a critical role of the carbonyl group (but not NH group, see below) for the ligandreceptor interaction. As this modification led to a total loss of activity, we refrained from performing O-methylation with PqsR antagonists. The two N-methylated derivatives 4 and 5 revealed a moderate antagonistic activity with improved solubility compared with 1 (Tables 1 and 2 ). This result indicates the importance of the NH hydrogen for antagonistic activity. The better solubility might be due to the disruption of intermolecular interactions.
Compound class 2. Introduction of oxygen into the alkyl side chain of the antagonists 1 and 2 close to the quinolone core (7 and 8, Tables 1 and 2 ) resulted in a moderate antagonistic activity and an enhanced solubility (6-15 times). Interestingly, in case the oxygen was located far from the quinolone core (10 and 11), the potency was dramatically decreased (32-69 fold), whereas the solubility was strongly increased (15-66 fold). Similar as observed for the antagonists, the oxygen far from the core also made the agonists less potent (comparing 6 and 9, (Table 1 and Table 2 ). Compound 26 with 3-carboxamide, as described in a previous work [22] , is a potent antagonist. Overall, the result implies that substituents at the 3-position are of decisive impotance for the ligand functionality. In the next step the selected antagonists were evaluated for their effects on the production of the autoinducer PQS and the virulence factor pyocyanin in P.
aeruginosa. Similar to the potent anti-virulence compound 26, 16 with a hydroxymethyl group at the 3-position was able to efficiently repress the biosynthesis of PQS and pyocyanin, whereas all compounds unsubstituted in 3-position (4, 7, 8, 10
and 11) were less active ( Table 2 ). Beside this low antagonistic activity toward PqsR, the metabolic susceptibility in 3-position shall play a critical role for the low effectiveness of the unsubstituted compounds in P. aeruginosa as previously described for antagonist 2 [22] .
Metal-chelating properties lead to growth inhibition of the bacteria via destabilization of the outer membrane [23, 24] or reduction of iron availability [25] , which is therefore unwanted for an anti-virulence strategy. The CAS iron chelation assay [26] showed that the most potent antagonists 16 and 26 do not have such undesirable properties (data not shown). As expected, no growth inhibition was observed for all tested antagonists in the PQS and pyocyanin assays (data not shown), indicating that their QS or virulence factor inhibitory effects are not caused via impairing bacterial viability.
Conclusion
Aiming at the development of more soluble and potent PqsR-targeting QSIs for an anti-virulence therapy, four classes of new quinolone compounds were designed and 
Experimental
Chemistry
Chemical and Analytical Methods. 
2-Heptyl-4-methoxyquinoline (3)
A mixture of HHQ (200 mg, 0.82 mmol, 1.0 equiv), Cs 2 CO 3 (410 mg, 1.26 mmol, 1.5 equiv) and dry DMF (5 mL) was stirred at room temperature for 1h. Methyl iodide (0.61 g, 4.32 mmol, 5.0 equiv) was added dropwise and the mixture was stirred for further 48h. The reaction was poured onto water (16 mL) and diluted with chloroform (25 mL). The organic layer was washed with water (16 mL), dried over sodium sulfate and concentrated under reduced pressure [29] . After column chromatography on silica gel (twice, dichloromethane/methanol, 130/1 and n-hexane/ethyl acetate, 
2-Heptyl-1-methyl-6-(trifluoromethyl)quinolin-4(1H)-one (4)
Methyl iodide (0.46 g, 3.24 mmol, 10.1 equiv) was added to a solution of 1 (100 mg, 0.32 mmol, 1.0 equiv), KOH (56 mg, 1.00 mmol, 3.1 equiv) in methanol (1 mL) and the mixture was stirred over night at room temperature. After the precipitate was removed by filtration, the solvent was evaporated under reduced pressure [30] . After column chromatography on silica gel (dichloromethane/methanol, 100/1) the product was isolated as a white solid (25 mg, 0.08 mmol, 25%), mp 125. 
2-Hexyl-1-methyl-6-(trifluoromethyl)quinolin-4(1H)-one (5)
The title compound was prepared using the same method as for the synthesis of 4 from 36 (100 mg, 0.34 mmol). After column chromatography on silica gel (dichloromethane/methanol, 100/1) the product was isolated as a white solid (30 mg, 0.10 mmol, 28%), mp 101.2-103.9 °C. 
2-(Pentyloxymethyl)quinolin-4(1H)-one (6)
The title compound was prepared according to procedure A from 33 (2.16 g, 10 mmol) and aniline (0.93 g, 10 mmol). 
2-(Pentyloxymethyl)-6-(trifluoromethyl)quinolin-4(1H)-one (7)
The title compound was prepared according to procedure A from 33 (2.16 g, 10 mmol) and 4-(trifluoromethyl)aniline (1.61 g, 10 mmol). After recrystallization from ethanol the product was isolated as a white solid ( 
6-Nitro-2-(pentyloxymethyl)quinolin-4(1H)-one (8)
A solution of 6 (80 mg, 0.33 mmol) in conc. H 2 SO 4 (1 mL) was cooled to 0 °C, and a mixture of conc. H 2 SO 4 (32 μL) and conc. HNO 3 (32 μL) was added slowly, maintaining the temperature at 0 °C. After the addition was complete, the mixture was allowed to reach room temperature with stirring for additional 2 h. The solution was poured onto ice, and the resulting precipitate was filtered and washed with water to give crude product [31] . After preparative thin layer chromatography on silica gel (dichloromethane/methanol, 20/1) the product was isolated as a yellow solid (25 mg, 0.09 mmol, 27%). mp 187.3-189.6 °C. 
2-(4-Ethoxybutyl)quinolin-4(1H)-one (9)
The title compound was prepared according to procedure A from 34 (0.65 g, 3.0 mmol) and aniline (280 mg, 3.0 mmol). 
2-(4-Ethoxybutyl)-6-(trifluoromethyl)quinolin-4(1H)-one (10)
The title compound was prepared according to procedure A from 34 (1. 
2-(4-Ethoxybutyl)-6-nitroquinolin-4(1H)-one (11)
Compound 24 (150 mg, 0.45 mmol) was carefully purged with nitrogen under stirring, then slowly heated past its melting point to 310 °C under inert atmosphere with continued stirring for 8 min. The reaction was cooled to room temperature after the evident evolution of carbon dioxide ceased. The resulting solid was dissolved in a dichloromethane/methanol (15/1) solution. Insoluble material was removed by filtration and the solvents were removed under reduced pressure [32] . The residue was purified by column chromatography on silica gel (dichloromethane/methanol, 60/1) to
give the product as a yellow solid (103 mg, 0.36 mmol, 80%), mp 232.9-233.8 °C. 
2-Heptyl-3-nitroquinolin-4(1H)-one (12)
At 110 °C conc. HNO 3 (65% w/w, 15 µL, 0.30 mmol, 2.5 equiv) was added to a stirred suspension of HHQ (30 mg, 0.12 mmol, 1.0 equiv) in propionic acid (3 mL).
The reaction mixture was heated for further 2 h with vigorous stirring. 
3-Amino-2-heptylquinolin-4(1H)-one (13)
A suspension of 12 (40 mg, 0.14 mmol, 1.0 equiv) in ethanol (2 mL) was heated at 
2-Heptyl-3-(hydroxymethyl)quinolin-4(1H)-one (15)
At 0 °C LiAlH 4 (120 mg, 3.16 mmol, 2.0 equiv) was added to a stirred solution of 17 (500 mg, 1.59 mmol, 1.0 equiv) in dry THF (30 mL). After stirring at room temperature for 2 h ethyl acetate (10 mL) was added at 0 °C and after filtration the solvent was removed under reduced pressure [34] . 
Ethyl 2-heptyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (17)
The 
Ethyl 6-nitro-4-oxo-2-(pentyloxymethyl)-1,4-dihydroquinoline-3-carboxylate (19)
The title compound was prepared according to procedure B from 33 (234 mg, 1. 
Ethyl 2-(4-ethoxybutyl)-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylate (20)
The title compound was prepared according to procedure B from 34 (1.7 g, 7.87 mmol), sodium hydride (50-65% w/w, 360 mg, 7.50 mmol) and 6-nitro-1H-benzo[d] [1, 3] oxazine-2,4-dione (1.57 g, 7.55 mmol) After column chromatography on silica gel (n-hexane/ethyl acetate, 1.2/1) and recrystallization from ethyl acetate the product was isolated as a yellow solid (2.6 g, 7.18 mmol, 95%), mp 210.4-211.7 °C. 
2-Heptyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (21)
The title compound was prepared according to procedure B from 17 (50 mg, 0.16 mmol). The product was isolated as a white solid (32 mg, 0.11 mmol, 69%), mp 219.4-221.7 °C. 
6-Nitro-4-oxo-2-(pentyloxymethyl)-1,4-dihydroquinoline-3-carboxylic acid (23)
The title compound was prepared according to procedure B from 19 (400 mg, 1.10 mmol). The product was isolated as a yellow solid (262 mg, 0.78 mmol, 71%), mp 149.8-150.3 °C. 
2-(4-Ethoxybutyl)-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (24)
2-Heptyl-4-oxo-1,4-dihydroquinoline-3-carboxamide (25)
N
2-Heptyl-N-hydroxy-6-nitro-4-oxo-1,4-dihydroquinoline-3-carboxamide (28)
The title compound was prepared using the same method as for the synthesis of 27 
Ethyl 2-heptyl-4-oxo-1,4-dihydro-1,6-naphthyridine-3-carboxylate (29)
The title compound was prepared according to procedure B from 32 (1.6 g, 7.48 mmol), sodium hydride (50-65% w/w, 357 mg, 7.44 mmol) and 1H-pyrido [4,3- 
Physicochemical properties 4.2.1 Determination of water solubility by HPLC
A calibration curve was made by plotting the area under the curve at 254 nm (UV by HPLC, for compound 7 at 245 nm) against the concentration of each compound injected after performing a serial dilution (25 μM to 0.781 μM in methanol). A saturated solution containing 2% DMSO was then made for each compound in PBS (pH 7.4) by performing dilution using a 10 mM DMSO stock solution of each compound. This solution was sonicated for 30 minutes and shaken at room temperature for 10 hours, filtered and injected into the HPLC to compare the area found at wavelength 254 nm (for compound 7 at 245 nm) with the previously made calibration curve [21] . 
CAS iron-chelation assay
Reporter gene assay in E. coli
The ability of the compounds to either stimulate or antagonize the PqsR-dependent transcription was analysed as previously described [17] using a β-galactosidase reporter gene assay in E. coli expressing PqsR. Briefly, a culture of E. coli DH5α cells containing the plasmid pEAL08-2, which encodes PqsR under the control of the tac promoter and the β-galactosidase reporter gene lacZ controlled by the pqsA promoter, were co incubated with test compound. Antagonistic effects of compounds were assayed in the presence of 50 nM PQS. After incubation, β-galactosidase activity was measured spectralphotometrically at OD 420nm using POLARstar Omega (BMG Labtech, Ortenberg, Germany) and expressed as percent stimulation of controls. For the determination of IC 50 values, compounds were tested at least at eight different concentrations.
4.3.2.Quantification of extracellular PQS levels
Extracellular levels of PQS produced by PA14 were quantified by UHPLC-MS/MS using the method of Maurer et al. [40] For each sample, cultivation and sample workup were performed in triplicates. Inhibition values of PQS formation were normalized to OD 600 .
Pyocyanin assay
For analysis of pyocyanin formation, cultivation procedure was the same as for PQS quantification with the exception of using PPGAS medium. Pyocyanin produced by PA14 was quantified using the method of Essar et al. [41] with some modifications, as described in detail by Klein et al. [42] . Briefly, 900 μL of each culture were extracted with 900 μL of chloroform and 800 μL of the organic phase reextracted with 250 μL of 0.2 M HCl. OD 520 was measured in the aqueous phase using FLUOstar Omega (BMG Labtech, Ortenberg, Germany). For each sample, cultivation and sample work-up were performed in triplicates. Inhibition values of pyocyanin formation were normalized to OD 600 .
